Cathie Wood’s Ark Investment increases holdings in Eli Lilly amid record $30 billion annual sales for its GLP-1 drug tirzepatide.
Ark Investment Management, led by Cathie Wood, has expanded its position in Eli Lilly (LLY) as the pharmaceutical firm’s GLP-1 drug tirzepatide generated $30 billion in annual sales last year. The drug, approved four years ago, treats diabetes, weight loss, and obstructive sleep apnea, driving significant revenue growth for Lilly.
Eli Lilly’s stock has surged over 1,600% in the past decade, outperforming broader equities. The company’s pipeline includes new GLP-1 products like Foundayo, an oral alternative, and retatrutide, targeting additional patient segments. Analysts expect continued momentum in the anti-obesity market.
The firm’s focus on differentiated therapies positions it for sustained earnings growth, with tirzepatide’s success underscoring its leadership in the GLP-1 space.